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Background: Patient-reported symptom and health-related qual-
ity of life (HRQoL) benefit of afatinib, a novel, irreversible, ErbB 
Family Blocker, was investigated in a double-blind, randomized, 
phase IIb/III trial (LUX-Lung 1).
Methods: Five hundred and eighty-five patients with lung adenocar-
cinoma (stage IIIb/IV), who had progressed after chemotherapy (1–2 
lines) and at least 12 weeks of erlotinib or gefitinib, were random-
ized (2:1) to receive either afatinib plus best supportive care (BSC) 
or placebo plus BSC. Symptom and HRQoL benefit were measured 
using the lung cancer-specific European Organisation for Research 
and Treatment of Cancer (QLQ-C30/LC13)  and EuroQol (EQ-5D) 
questionnaires. Non–small-cell lung cancer–related symptoms 
(cough, dyspnea, and pain) were prespecified using three preplanned 
analyses (percentage of patients improved/worsened/stable, change 
in scores over time, and time to deterioration of scores).
Results: Compared with patients on placebo, a significantly higher 
proportion of afatinib-treated patients showed an improvement in 
cough (p < 0.0001), dyspnea (p = 0.006), and pain (p < 0.0001). 
Afatinib also significantly improved the mean scores over time for 
cough (p < 0.0001), dyspnea (p = 0.0161), and pain (p = 0.0056); 
significantly delayed the time to deterioration for cough (p < 0.001); 
and showed a trend in delaying dyspnea (p = 0.170) and pain (p = 
0.287). Consistent with the adverse-event profile of afatinib, a sig-
nificantly (p < 0.05) higher proportion of afatinib-treated patients 
showed worsening of diarrhea, sore mouth, dysphagia, and appe-
tite scores. However, compared with placebo, afatinib significantly 
(p < 0.05) improved QoL assessed with the EQ-5D questionnaire and 
global health status/QoL, physical functioning, and fatigue, which 
were assessed with the European Organisation for Research and 
Treatment of Cancer questionnaires.
Conclusion: In the LUX-Lung 1 trial, the addition of afatinib to 
BSC significantly improved non–small-cell lung cancer–related 
symptoms (cough, dyspnea, and pain), fatigue, physical functioning, 
and HRQoL and significantly delayed time to deterioration of cough.
Key Words: Afatinib, Quality of life, Symptom benefit, Non–small-
cell lung cancer, Phase IIb/III trial.
(J Thorac Oncol. 2013;8: 229–237)
Lung cancer remains a leading cause of cancer death worldwide, for both men and women.1 Approximately 
90% of patients with advanced non–small-cell lung cancer 
(NSCLC) experience two or more disease-related symptoms, 
which may result in psychological distress. Disease-related 
symptoms commonly include pulmonary symptoms such as 
cough, dyspnea, and the general symptoms of fatigue, pain, 
and anorexia.2 These symptoms have a negative impact on a 
patient’s health-related quality of life (HRQoL); dyspnea and 
fatigue have been shown to interfere with at least one daily life 
activity in the majority of patients, and pain interferes with 
one daily life activity in approximately 40% of patients.2 High 
degrees of psychological distress experienced by lung cancer 
patients influence the emotional well-being in both patients 
and their families. Given the impact that disease-related 
symptoms have on patient HRQoL, it is not surprising that 
68% of patients would prefer a therapy that improved disease-
related symptoms without prolonging life, as opposed to one 
that marginally improved survival without symptom benefit.3
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Therefore, patient-reported outcomes (PROs) of treat-
ment (including symptom and HRQoL outcomes) are con-
sidered to be important, in addition to efficacy and safety 
endpoints, in patients with advanced NSCLC. Furthermore, 
PROs should be viewed as components of the total value of 
a treatment and, together with these other cancer endpoints, 
provide a comprehensive picture of the benefits and risks of 
anticancer therapies, as discussed during an American Society 
of Clinical Oncology/U.S. Food and Drug Administration 
workshop on endpoints for the approval of cancer drugs for 
lung cancer, in 2003. A similar position has been taken by the 
European Medicines Agency.4,5
Afatinib is a novel, orally bioavailable, irreversible, 
small-molecule ErbB Family Blocker that inhibits epidermal 
growth factor receptor (EGFR, also known as ErbB1), human 
epidermal growth factor receptor (HER2) (ErbB2), and ErbB4 
receptor kinases.6,7 Clinical studies have confirmed the effi-
cacy of afatinib in EGFR-tyrosine kinase inhibitor (TKI)–naive 
patients with activating EGFR mutations.8,9 Preclinically, the 
activity of afatinib extends beyond the common EGFR muta-
tions to the T790M mutation, the main mechanism of acquired 
resistance to the reversible EGFR-TKIs, erlotinib and gefitinib.7 
Therefore, afatinib offers a potential alternative for patients who 
have progressed after chemotherapy and EGFR-TKI therapy.
The efficacy and safety of afatinib in EGFR-TKI pre-
treated patients was investigated in a randomized, double-
blind, multicenter phase IIb/III trial (LUX-Lung 1).10 The 
primary objective of this trial was to investigate the efficacy 
of afatinib monotherapy (plus best supportive care [BSC]) 
compared with placebo (plus BSC) in patients with progres-
sive, advanced NSCLC in the refractory setting. One of the 
secondary objectives was to assess patient-reported symptom 
and HRQoL outcomes, which are presented here.
PATIENTS AND METHODS
Study Population
Adult patients with pathologically confirmed NSCLC 
stage IIIb/IV adenocarcinoma (tumor, node, metastasis classi-
fication system by the International Union Against Cancer, 6th 
edition), who had progressed on one or two lines of cytotoxic 
chemotherapy (one of which was platinum based), and had 
progressive disease after at least 12 weeks of treatment with 
erlotinib or gefitinib, were eligible for inclusion.10
Study Design
Patients were randomized 2:1 to receive BSC plus 
either oral afatinib 50 mg once daily or placebo until disease 
progression, death, or withdrawal because of adverse events 
(AEs). The primary study endpoint was overall survival 
(OS). Secondary endpoints included progression-free sur-
vival (PFS), objective tumor response (Response Evaluation 
Criteria in Solid Tumors criteria), safety, and HRQoL.
Patient-Reported Outcomes Assessments
Patient-reported symptom and HRQoL benefits 
were assessed using the self-administered cancer-specific 
European Organisation for Research and Treatment of 
Cancer (EORTC) quality of life questionnaire (QLQ)-Core 
30 (C30),11 the lung cancer-specific EORTC QLQ-Lung 
Cancer 13 (LC13),12 and the EuroQol (EQ-5D)13 question-
naire. The QLQ-C30 questionnaire incorporates five func-
tional scales (physical, role, cognitive, emotional, and social), 
three symptom scales (fatigue, pain, and nausea/vomiting), a 
global health status/QoL scale, and a number of single items 
(dyspnea, loss of appetite, sleep disturbance, constipation, 
diarrhea, and financial impact). The QLQ-LC13 question-
naire incorporates one multi-item scale to assess dyspnea, 
and a series of single items assessing pain, coughing, sore 
mouth, dysphagia, peripheral neuropathy, alopecia, and use 
of pain medication.
For each scale/item, a linear transformation was 
applied to standardize the raw score to a range from 0 to 
100, with 100 representing best possible function/QoL 
for functional scales, and highest burden of symptoms for 
symptom scales and symptom items. A 10-point change in 
an item or domain is perceived to be clinically meaningful.14 
Therefore, the percentage of patients who were classified as 
improved (≥ 10-point increase for functioning scales and ≥ 
10-point reduction for symptom domains or items from base-
line score), stable or worsened (≥ 10-point reduction for func-
tioning scales and ≥ 10-point increase for symptom scales or 
items from baseline score), with respect to each of the EORTC 
QLQ-C30 and QLQ-LC13 scales/items, was examined.14 In 
addition, time to deterioration of an item/domain score was 
defined as the time from randomization to the first appearance 
of a score that was 10 points or more lower or higher than 
the baseline score (≥ 10-point reduction for functioning scales 
and ≥ 10-point increase for symptom scales or items).
The EQ-5D is a disease-generic questionnaire that com-
prises the EQ-5D and EQ-visual analogue scale (VAS). The 
EQ-5D measures five dimensions of health (mobility, self-
care, usual activities, pain/discomfort, and anxiety/depres-
sion). Each dimension comprises three levels (no problems, 
some/moderate problems, and extreme problems). Utility 
scores range from 0 to 1 and were calculated from the five 
EQ-5D item scores using the U.K. preference weights.15 The 
EQ-VAS records the patient’s self-rated health status on a ver-
tical, graduated (0–100) VAS.
Per protocol, the EORTC QLQ-C30, QLQ-LC13, and 
EQ-5D questionnaires were scheduled to be completed every 
2 weeks during the first 2 months, every 4 weeks thereafter, at 
the end-of-treatment (EOT) visit, and during the first follow-up 
visit. Questionnaires were administered more frequently during 
the first 2 months to maximize data capture before patients 
discontinued treatment, especially in the placebo treatment 
arm. To assess symptoms and HRQoL related to afatinib and 
placebo treatment, questionnaires were only completed up to 
the first follow-up visit. To attribute any observed symptom 
or HRQoL benefit directly to afatinib or placebo, the use of 
concomitant medications was assessed in both the afatinib and 
placebo treatment arms at baseline and during the trial.
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Statistical Methods and Analyses
The intention-to-treat data set was used for all EORTC 
QLQ-C30, QLQ-LC13, and EQ-5D analyses. The NSCLC-
related symptoms of cough, dyspnea, and pain were pre-
specified because of the relevance of these symptoms and to 
avoid multiplicity.16 Cough (question 1 on the QLQ-LC13), 
dyspnea (composite of questions 3–5 on the QLQ-LC13), 
and pain scores (composite of questions 9 and 19 on the 
QLQ-C30) were assessed. All items and alternative mea-
sures for dyspnea and pain were examined descriptively for 
consistency and comparison.
Analyses included a comparison of the percentage 
of patients considered to have improved, become stable or 
worsened for each of the QLQ-C30 and QLQ-LC13 sum-
mary scales or single items in the two treatment arms (χ2 
square test). Time to deterioration was analyzed similar to 
OS and PFS (log-rank test stratified by baseline Eastern 
Cooperative Group [ECOG] performance score [PS; 0 or 
1 versus 2] and sex). The Hochberg–Bonferroni procedure 
was applied to the group of comparisons comprising the 
three symptom scales or single items.17 Patients who died 
before deteriorating but within 4 weeks of treatment discon-
tinuation were considered to have deteriorated at the time 
of death. Disease progression without scale deterioration 
was censored at the time of the last EORTC assessment; 
patients with no patient-reported outcomes assessments 
were censored at day 1. If a patient-reported outcome 
assessment was missed but followed by another assessment 
and deterioration occurring during that time period, the 
time to deterioration was defined as the midpoint between 
the two observed assessments. The longitudinal analysis 
in this study used a mixed-effects growth-curve model, 
with the average profile over time for each endpoint being 
described by a piecewise linear model that allowed the 
slope to change at predefined time points (2, 4, 8, and 12 
weeks). QLQ-C30 and QLQ-LC13 summary scales or sin-
gle items, EQ-5D utility scores, and EQ-VAS scores were 
analyzed using this model. All analyses were prespecified 
before unblinding the study data.
Terms in the model were randomized treatment, actual 
time since randomization, ECOG PS at baseline, and sex. 
For each treatment group, the area under the estimated 
growth curve (AUC) up to the median follow-up time for 
each EORTC/EQ-5D score was calculated. The AUC divided 
by the median follow-up time was interpreted as the mean 
EORTC/EQ-5D score, up to the median follow-up time. 
Between-treatment arm differences for the proportion of 
patients improved, the time to deterioration and longitudi-
nal analysis when described as significant refer to statistical 
significance.
Sensitivity analyses were carried out for the propor-
tion of patients improved and the longitudinal analysis. The 
durability of improvement was tested by requiring patients 
to have an improvement of 10 points or more over at least 
two assessments. Joint models were fitted using SAS 
NLMixed, extending the basic model described above to 
test the results of the longitudinal analyses for uncertainty 
associated with missing data. Of several candidates for the 
time to event that is included in the joint model, time to 
randomized permanent discontinuation of last study medi-
cation and time to last EORTC/EQ-5D assessment were 
chosen.18
RESULTS
Patient Population
In total, 585 patients were randomized from May 2008 
to September 2009 across 15 countries in North America, 
Europe, and Asia (390 patients received afatinib and 195 
patients received placebo). The patient characteristics between 
the two treatment arms were well balanced. The study popula-
tion comprised a highly selected population (histology: 98% 
adenocarcinoma, 58% East Asian, 60% women, 63% never-
smokers, 25% ECOG PS of 0, 68% ECOG PS of 1; median 
age of 58 years) that was very sensitive to previous EGFR 
inhibition. Indeed, 45% of patients had achieved a partial 
or complete response on previous EGFR-TKI therapy, with 
a median treatment time of 43 weeks. Of 141 patients with 
tumor tissue available for optional testing, 68% were positive 
for EGFR mutation.10
Brief Summary of Other Clinical Outcomes
At the time of database lock, median OS was 10.8 
months for the afatinib arm and 12 months for the placebo 
arm (HR 1.08, [95% confidence interval 0.86, 1.35], p = 0.74). 
Afatinib significantly improved PFS compared with placebo 
(median 3.3 versus 1.1 months, HR 0.38, [0.31, 0.48], p < 
0.0001). In addition, patients in the afatinib arm had a disease-
control (≥ 8 weeks) rate (partial response/stable disease) of 
58%, compared with 18% in the placebo arm.10
Compliance with Patient-Reported Assessments
Compliance rates for each treatment arm are presented 
in Table 1. High compliance rates were observed (65%–
100%) up to week 24/EOT and were comparable across both 
treatment arms. Lower compliance rates were observed dur-
ing the first follow-up visit (45-46%), which occurred 28 days 
after the EOT visit. The main reason for missing EORTC and 
EQ-5D questionnaires was treatment discontinuation, particu-
larly in the placebo treatment arm, justifying the usefulness of 
completing the EORTC questionnaires every 2 weeks during 
the first 2 months.
Concomitant Medication
At baseline, no difference between treatment arms was 
observed with regard to the proportion of patients receiving 
symptomatic treatment for dyspnea (3% versus 3%), cough 
(15% versus 15%), and pain (49% versus 48%) for afatinib 
versus placebo, respectively. During the treatment period, 
concomitant use of such medications was also similar between 
the two treatment groups: dyspnea (6% versus 4%), cough 
(23% versus 20%), and pain (60% versus 57%) for afatinib 
versus placebo, respectively.
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Baseline Symptoms and HRQoL Scores
At baseline, mean EORTC scores for the three prespeci-
fied NSCLC related symptoms–cough, dyspnea, and pain–
were generally low ranging from 24–31 (Table 2), suggesting 
that patients had low symptom levels. Similarly, the EQ-5D 
U.K. utility and EQ-VAS scores were found to be favorable 
(0.727 and 69.5, respectively). This finding was consistent 
with patients’ good ECOG PS at baseline (PS 0, 25%; PS 1, 
68%; PS 2, 8%). Common Terminology Criteria of Adverse 
Events (CTCAE) also demonstrate low rates of cough (30%), 
dyspnea (17%), and chest pain (12%) across both treatment 
arms at baseline.
Proportion of Patients with Improved 
Symptoms and HRQoL Scores
A significantly greater percentage of patients in 
the afatinib treatment arm showed improvements for the 
prespecified NSCLC-related symptoms of cough (46% versus 
25%, p < 0.0001), dyspnea (51% versus 36%, p = 0.0060), 
and pain (50% versus 32%, p < 0.0001) as measured with 
the EORTC questionnaires, compared with the placebo 
treatment arm (Fig. 1). Significant benefits favoring patients 
treated with afatinib were also observed for the single 
items of shortness of breath (40% versus 25%, p = 0.0014), 
pain in chest (40% versus 24%, p = 0.0014), pain in arm or 
shoulder (41% versus 27%, p = 0.0044), and pain in other 
parts (36% versus 26%, p < 0.0037). Conversely, a significant 
worsening of scores was observed for the symptoms of 
appetite loss (53% versus 40%, p < 0.0001), diarrhea (83% 
versus 17%, p < 0.0001), sore mouth (76% versus 17%, 
p < 0.0001), and dysphagia (46% versus 17%, p < 0.0001) 
for patients treated with afatinib compared with patients 
on placebo, respectively. Afatinib showed a significantly 
greater percentage of patients with improvement in fatigue 
symptom scores compared with placebo (53% versus 40%, 
p < 0.0007). Overall, improvements were observed for global 
health status/QoL (38% versus 29%, p < 0.084) for afatinib-
treated patients compared with patients treated with placebo, 
respectively.
Time to Deterioration of Symptom 
and HRQoL Scores
Afatinib significantly delayed the time to deterioration 
for cough (HR 0.60, [0.44, 0.81]), and showed a trend in 
TABLE 1.  Patient Compliance Rates with EORTC and EQ-5D Questionnaires by Treatment Arm
Afatinib + BSC Placebo + BSC
Total No. of  
Patients, N
Patients Completing EORTC  
and EQ-5D Questionnaires, n (%)
Total No. of  
Patients, n
Patients Completing EORTC and 
EQ-5D Questionnaires, n (%)
Baseline 390 367 (94.1) 195 182 (93.3)
Week 2 389 346 (88.9) 195 166 (85.1)
Week 4 369 302 (81.8) 103 89 (86.4)
Week 6 302 247 (81.8) 75 62 (82.7)
Week 8 287 231 (80.5) 66 49 (74.2)
Week 12 221 158 (71.5) 39 26 (66.7)
Week 16 174 149 (85.6) 22 19 (86.4)
Week 20 158 103 (65.2) 20 15 (75.0)
Week 24 105 85 (81.0) 9 9 (100.0)
End of trial 380 275 (72.4) 194 149 (76.8)
FUV 1 326 148 (45.4) 179 82 (45.8)
BSC, best supportive care; EORTC, European Organisation for Research and Treatment of Cancer; FUV, follow-up visit.
TABLE 2.  EORTC Questionnaire Scores at Baseline
EORTC QLQ-C30 or LC13 Item or Domain
Afatinib + BSC Placebo + BSC
Mean Score (SD) n Mean Score (SD) n
Cough (Q1 from QLQ-LC13) 30.7 (26.2) 361 28.9 (27.2) 182
Dyspnea (Q3–Q5 from QLQ-LC13) 24.2 (21.2) 361 24.0 (21.4) 182
Shortness of breath (Q8 from QLQ-C30) 28.3 (27.7) 362 25.6 (26.9) 182
Pain (Q9, Q19 from QLQ-C30) 27.8 (27.0) 365 26.8 (25.7) 182
Pain in chest (Q10 from QLQ-LC13) 21.1 (24.5) 361 18.3 (23.2) 180
Pain in arm or shoulder (Q11 from QLQ-LC13) 22.1 (26.3) 360 21.5 (26.5) 181
Pain in other parts (Q12 from QLQ-LC13) 23.6 (27.5) 346 24.2 (28.7) 168
Lower scores indicate that patients experience fewer or no problems on a scale of 0–100.
EORTC, European Organisation for Research and Treatment of Cancer; BSC, best supportive care; SD, standard deviation.
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delaying dyspnea (HR 0.84, [0.66, 1.06]) and pain (HR 0.88, 
[0.68, 1.13]) (Fig. 2). For dyspnea, the potential benefit of 
afatinib compared with placebo was more apparent when 
items relating to physical exertion were assessed, such as 
dyspnea while walking (HR 0.72, [0.55, 0.95]), dyspnea 
while climbing stairs (HR 0.69, [0.52, 0.92]) and the 
single item of shortness of breath (HR 0.73, [0.55, 0.97]). 
Afatinib treatment was favored over placebo for time to 
deterioration for the item have pain 0.73, [0.55, 0.96]), pain 
in chest (HR 0.61, [0.45, 0.84]), pain in arm or shoulder 
(HR 0.71, [0.52, 0.98], constipation (HR 0.46, [0.34, 0.62]), 
hemoptysis (HR 0.89, [0.56, 1.41]), fatigue (HR 0.97, [0.78, 
1.22]), and insomnia (HR 0.70, [0.53, 0.93]). Conversely, a 
significantly shorter time to deterioration was observed for 
afatinib for the EORTC questionnaire scores for appetite 
loss (HR 1.29, [1.00, 1.66]), dysphagia (HR 2.17, [1.54, 
3.06]), sore mouth (HR 5.88, [4.21, 8.21]), and diarrhea 
(HR 7.88, [5.63, 11.02]).
Coughing (Q1 from QLQ–LC13)
0
Dyspnea (Q3–Q5 from QLQ–LC13)
Dyspnea, rested (Q3 from QLQ–LC13)
Dyspnea, walked (Q4 from QLQ–LC13)
Dyspnea, climbed stairs (Q5 from QLQ–LC13)
Shortness of breath (Q8 from QLQ–C30)
Pain (Q9, Q19 from QLQ–C30)
Having pain (Q9 from QLQ–C30)
Pain affecting daily activities (Q19 from QLQ–C30)
Pain in chest (Q10 from QLQ–LC13)
Pain in arms or shoulders (Q11 from QLQ–LC13)
Pain in other parts (Q12 from QLQ–LC13)
10 20 30 40 50 60 70
Patients improved (%)
Placebo
Afatinib
p=0.0060
p<0.0001
p=0.3439
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p=0.0014
p<0.0001
p<0.0001
p<0.0001
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p=0.0044
p=0.0037
24.6
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15.2
18.3
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49.9
24.6
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FIGURE 1.  Percentage of patients 
with improvement in the three 
prespecified symptoms of cough, 
dyspnea, and pain. Improvement was 
defined as ≥ 10-point increase for 
functioning scales and ≥ 10-point 
reduction for symptom domains 
or items from baseline score. The 
number of patients included in the 
analysis of each of the listed items/
domains was n = 339–359 (afatinib) 
and n = 153–171 (placebo).
Coughing (Q1 from QLQ–LC13) 0.60 (0.44, 0.81)
0.25 0.5 1 2
HR (95% CI)
Dyspnea (Q3–Q5 from QLQ–LC13)
Dyspnea rested (Q3 from QLQ–LC13)
Dyspnea walked (Q4 from QLQ–LC13)
Dyspnea climbed stairs (Q5 from QLQ–LC13)
Shortness of breath (Q8 from QLQ–C30)
Pain (Q9, Q19 from QLQ–C30)
Have pain (Q9 from QLQ–C30)
Pain affecting daily activities (Q19 from QLQ–C30)
Pain in chest (Q10 from QLQ–LC13)
Pain in arm or shoulder (Q11 from QLQ–LC13)
Pain in other parts (Q12 from QLQ–LC13)
0.84 (0.66, 1.06)
0.87 (0.64, 1.19)
0.72 (0.55, 0.95)
0.69 (0.52, 0.92)
0.73 (0.55, 0.97)
0.88 (0.68, 1.13)
0.73 (0.55, 0.96)
0.99 (0.76, 1.31)
0.61 (0.45, 0.84)
0.71 (0.52, 0.98)
0.80 (0.60, 1.07)
FAVORS AFATINIB             
FIGURE 2.  Time to deterioration 
analysis for the three prespecified 
symptoms of cough, dyspnea, and 
pain. Time to deterioration was ana-
lyzed using log-rank test stratified by 
baseline ECOG PS and sex. The time 
to deterioration analysis included 
all randomized patients, that is, n = 
390 (afatinib) and n = 195 (placebo). 
Patients who did not complete any 
questionnaires were either censored 
on day 1 or considered deteriorated 
if they died within 4 weeks after 
randomization.
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Afatinib was found to delay the time to deterioration 
for global health status/QoL (HR 0.78, [0.62, 1.00]) and the 
functioning scales of emotional (HR 0.87, [0.65, 1.16]), phys-
ical (HR 0.81, [0.62, 1.05]), role (HR 0.81, [0.64, 1.03]), and 
social (HR 0.97, [0.75, 1.25]) functioning. No difference in 
time to deterioration was observed for the remaining items or 
scales.
Longitudinal Analysis of Symptom 
and HRQoL Scores
Afatinib-treated patients had significantly better mean 
symptom scores up to the median follow-up time (13 weeks) 
for the prespecified symptoms: cough (–6.99 [95% confidence 
interval: –9.71, –4.27]), dyspnea (–2.68 [–4.86, –0.49]),  and 
pain (–4.02 [–6.87, –1.18]) (Fig. 3). Between-group differ-
ences in symptom scores favoring afatinib started at week 
2 and generally lasted throughout the study period. Patients 
in the afatinib treatment arm, who assessed their experi-
ence of dyspnea during physical activity demonstrated the 
largest difference in scores compared with patients in the 
placebo arm. The difference in means was also more pro-
nounced in favor of afatinib for the following items: have 
pain (–6.08 [–9.21, –2.96]), pain in chest (–5.60 [–8.03, 
–3.17]), pain in other parts (–4.04 [–7.37, –0.71]), pain in 
arm and shoulder (–6.26 [–8.91, –3.61]), and shortness of 
breath (–3.46 [–6.21, –0.71]).
Afatinib-treated patients also demonstrated signifi-
cantly better EORTC scores for the items constipation (dif-
ference in means, –9.96 [–12.3, –7.63]) and insomnia (–6.73 
[–9.69, –3.78]) compared with the patients in the placebo 
treatment arm. Furthermore, mean difference in scores for 
fatigue (–2.99 [–5.54, –0.45]), nausea and vomiting (–0.66 
[–2.66, 1.35]), financial differences (–1.11 [–3.82, 1.60]), 
and alopecia (–0.92 [–3.59, 1.76]) favored the afatinib treat-
ment arm. Conversely, the difference in mean scores for appe-
tite loss (4.71 [1.51, 7.91]), dysphagia (4.54 [2.28, 6.79]), 
peripheral neuropathy (2.41 [–0.27, 5.08]), sore mouth (21.04 
[18.24, 23.84]), and diarrhea (33.18 [30.13, 36.23]) favored 
the placebo treatment arm. No difference in mean score for 
hemoptysis (0.11 [–1.08, 1.30]) was observed.
Patients treated with afatinib also demonstrated sig-
nificantly better EORTC scores for global health status/QoL 
(difference in means, 3.29 [1.05, 5.53]) and physical function-
ing (3.49 [1.19, 5.79]) compared with patients in the placebo 
treatment arm. A positive trend favoring the afatinib treatment 
arm was also observed for the other functioning domains.
The longitudinal analysis was also performed for the 
EQ-5D utility score and EQ-VAS scores. HRQoL, when 
measured using those, was significantly better in the afatinib 
treatment arm compared with the placebo treatment arm. The 
mean EQ-5D utility score to median follow-up time was 0.71 
versus 0.67 ( p = 0.006) for the afatinib and placebo groups, 
respectively. For EQ-VAS, this was 67.4 versus 65.2 ( p = 
0.0205) for the afatinib and placebo groups, respectively.
Sensitivity Analyses
For the proportion of patients who had improved, the 
durability of improvement was tested. Patients were required 
to have an improvement of 10 points or greater over at least 
two assessments. The magnitude in the differences between 
treatment arms remained more than 10% and statistical signif-
icance was maintained. Findings of this analysis were there-
fore found to be robust.
For the longitudinal analysis, two separate analyses 
(1 including data until week 4 and 1 including data until week 
8) showed similar results. In addition, no notable differences 
in results were observed when data from the follow-up 
visit were removed. In addition, sensitivity analyses were 
carried out using a joint model,18 which is more general 
than a longitudinal model because it relaxes the missing 
data assumptions to missing at random that are conditional 
on the time to treatment termination or last EORTC/EQ-5D 
assessment. Results of these analyses were similar to those 
from the longitudinal model.
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FIGURE 3.  Results from the longitu-
dinal analysis for the three prespeci-
fied symptoms of cough, dyspnea, 
and pain. The longitudinal analysis 
uses a mixed-effects growth curve 
model with the average profile over 
time for each endpoint described by 
a piecewise linear model adjusted 
for baseline ECOG PS and sex. The 
number of patients included in the 
analysis for each of the listed items/
domains was n = 385–386 (afatinib) 
and n = 191 (placebo). ECOG PS, 
Eastern Cooperative Oncology Group 
performance status.
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Subgroup Analyses
To determine the influence of patient PS on the outcomes 
of the EORTC scores, two subgroup analyses were performed 
(ECOG PS 0 patients versus ECOG PS 1, 2 patients). For each 
of the three analyses (proportion of patients improved, time to 
deterioration, and longitudinal analyses), the symptom benefit 
associated with afatinib therapy was larger for patients with 
ECOG PS 1 and 2 compared with patients with ECOG PS 0 
(Fig. 4A–C).
Clinician-Reported Outcomes
Clinician-reported outcomes are derived from the 
reporting of AEs according to the CTCAE v3.0. Cough (any 
grade) was reported in 13% of afatinib-treated patients and 
19% of placebo-treated patients. Any-grade dyspnea was 
reported in 15% of patients treated with afatinib, compared 
with 13% of placebo-treated patients. When exposure was 
corrected to take into consideration the longer treatment dura-
tion for patients in the afatinib treatment arm, time to onset of 
cough and dyspnea was delayed in the afatinib arm compared 
with the placebo arm. By day 84, 25% of placebo-treated 
patients had experienced cough compared with 8% of afatinib-
treated patients (HR 0.41, p < 0.0001). By day 84, 13% of 
placebo-treated patients and 10% of afatinib-treated patients 
had experienced dyspnea (HR 0.80, p = 0.354). In general, 
the most frequent clinician-reported AEs (with a > 10% dif-
ference between treatment arms) were diarrhea, rash/acne, 
stomatitis, nail effect, and decreased appetite. Fewer patients 
in the placebo arm compared with the afatinib arm experi-
enced diarrhea of any grade (9% versus 87%) and decreased 
appetite (11% versus 31%).
DISCUSSION
This large, phase IIb/III study comparing afatinib plus 
BSC with placebo plus BSC demonstrated that afatinib sig-
nificantly improved the NSCLC-related symptoms of cough, 
dyspnea, and pain, while also significantly delaying deteriora-
tion of cough. An analysis of concomitant medication con-
firms that the benefit observed with afatinib is not the result 
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FIGURE 4.  Subgroup analyses with patients with ECOG PS 0 
versus ECOG PS 1, 2. A, Proportion of patients improved. The 
number of patients included in the analysis of the proportion 
of patients improved for each of the listed items/domains 
was for baseline ECOG = 0, n = 82 (afatinib) and n = 46 
(placebo); for baseline ECOG = 1 or 2, n = 274–277 (afatinib) 
and n = 125 (placebo). B, Time to deterioration. The time 
to deterioration analysis included all randomized patients: 
baseline ECOG = 0, n = 92 (afatinib), and n = 53 (placebo); 
for baseline ECOG = 1 or 2, n = 298 (afatinib), and n = 142 
(placebo). Patients who did not complete any questionnaires 
were either censored on day 1 or considered deteriorated if 
they died within 4 weeks after randomization. C, Longitudinal 
analysis. The number of patients included in the longitudinal 
analysis of each of the listed items/domains was n = 91 (afa-
tinib) and n = 53 (placebo) for ECOG PS 0, and n = 294–295 
(afatinib) and n = 138 (placebo) for ECOG PS 1–2. ECOG PS, 
Eastern Cooperative Oncology Group performance status.
236 Copyright © 2012 by the International Association for the Study of Lung Cancer
Hirsh et al. Journal of Thoracic Oncology  •  Volume 8, Number 2, February 2013
of patients receiving additional symptomatic treatment com-
pared with patients in the placebo arm.
Previous studies have shown that EGFR-TKIs are 
associated with the occurrence of diarrhea. The finding that 
afatinib treatment worsened the symptom of diarrhea cor-
relates with the higher rate of diarrhea reported as an AE in 
the afatinib treatment arm. Although diarrhea worsened in the 
afatinib treatment arm, and was more frequently observed as 
an AE compared with the placebo treatment arm, improve-
ments in overall global health status/QoL favored the afatinib 
treatment arm. In addition, few patient discontinuations were 
reported as being the result of the occurrence of diarrhea 
(3.6%), suggesting that the implementation of antidiarrheals 
and dose reductions were effective in allowing patients to con-
tinue afatinib treatment.
Patients enrolled in this trial had a good ECOG PS and 
relatively low symptom burden at baseline according to the 
CTCAE and EORTC scores for cough, pain, and dyspnea, 
in particular. Despite the low symptom burden at baseline, 
patients in the afatinib treatment arm were found to have sig-
nificantly better EORTC scores for cough, dyspnea, and pain, 
compared with patients receiving placebo. However, the dif-
ference in EORTC scores seemed to be more pronounced in 
patients with a baseline ECOG PS of 1 or 2 compared with 
those with an ECOG PS of 0.
Although patient compliance with the EORTC and 
EQ-5D questionnaires was high in both treatment arms, a sub-
stantial amount of data was missing in the placebo treatment 
arm because of early patient discontinuation. Results of the three 
main analyses, as well as the sensitivity analyses, confirmed the 
positive effect of afatinib on symptoms and HRQoL compared 
with placebo. Completing the EORTC and EQ-5D question-
naires every 2 weeks during the first 2 months provided more 
frequent data points to inform each of the three main analyses 
and the sensitivity analyses. Collecting EORTC and EQ-5D 
data beyond the first follow-up visit postprogression may have 
alleviated the issue of missing data; however, this could have 
led to the occurrence of several potential challenges in this 
study: the inclusion of EORTC and EQ-5D data that showed 
results no longer attributable to afatinib and placebo because 
of the initiation of subsequent treatment regimens, compliance 
(completion of questionnaire and timing of completion), and 
difficulties administering questionnaires. Although no EORTC 
and EQ-5D data were collected beyond the first follow-up visit, 
removing data from the first follow-up visit from the sensitivity 
analysis showed no notable differences in results, indicating the 
robustness of the initial analyses.
Over recent years, HRQoL-based measures have been 
increasingly incorporated into oncology phase III clinical tri-
als, mainly as secondary endpoints.19,20 A patient’s own assess-
ment of the benefit of anticancer therapy has been considered 
important from the persepective of a patient, physician, payer, 
and regulator and also in terms of the clinical measures of OS, 
PFS, and response. Most researchers and clinicians agree that 
measuring PROs, such as pain or physical function, is fun-
damental because of their impact on patient compliance and 
outcome. Furthermore, assessing symptom and HRQoL out-
comes demonstrates how positive PFS outcomes can translate 
into additional patient benefit.
Previous studies have demonstrated symptom and HRQoL 
benefits of different magnitudes after treatment with EGFR-
targeting therapy.21–24 One large, randomized, phase III study, 
BR.21, compared second- or third-line erlotinib treatment with 
placebo in patients with NSCLC and measured symptom and 
HRQoL outcomes using the EORTC questionnaires.22 Patients 
receiving erlotinib in BR.21 experienced significantly longer 
times to symptom deterioration and reported notable symptom 
improvements for cough, dyspnea, and pain compared with 
patients receiving placebo. Erlotinib was found to be associated 
with a significant worsening of diarrhea, sore mouth, hair 
loss, and significant improvements in emotional functioning, 
physical functioning, and global QoL. Patterns of symptom 
improvement and HRQoL were largely consistent with the 
findings from the LUX-Lung 1 study. In general, differences 
in NSCLC patient populations, compliance, selected HRQoL 
questionnaires, timing of assessments, HRQOL analyses, and 
whether the analyses and endpoints were prespecified require 
consideration when attempting to make cross-trial comparisons.
To conclude, the addition of afatinib to BSC improved 
not only PFS but also the NSCLC-related symptoms of cough, 
dyspnea, and pain, while also delaying deterioration of cough. 
Although afatinib treatment was associated with a worsen-
ing of diarrhea, overall HRQoL was found to be improved. 
Positive symptom and HRQoL data reported from this study, 
in addition to the previously reported efficacy data, support 
the use of afatinib in advanced NSCLC patients previously 
treated with an EGFR-TKI.
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